^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    NEJM
    Title:

    First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Excerpt:
    Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001)....Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.
    DOI:
    10.1056/NEJMoa1408440
    Trial ID:
    PROFILE 1014
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

    Excerpt:
    ...- ≥18，Pathologically proven ALK positive mutation in advanced non squamous non small cell lung cancer...
    Trial ID:
    NCT03647111
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

    Excerpt:
    ...- Positive for translocation or inversion events involving the ALK gene locus (e.g....
    Trial ID:
    ALCHEMIST
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

    Excerpt:
    ...- Positive for translocation or inversion events involving the ALK gene locus...
    Trial ID:
    NCT01500824
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

    Excerpt:
    ...- Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagnostic test....
    Trial ID:
    KEYNOTE 050
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

    Excerpt:
    ...- Positive for translocation or inversion events involving the ALK gene locus...
    Trial ID:
    PROFILE 1014
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

    Excerpt:
    ...- Positive for translocation or inversion events involving the ALK gene locus....
    Trial ID:
    NCT01639001